RecruitingPhase 2NCT07559370

Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria

Evaluating the Safety and Efficacy of Imatinib in Combination With Artemether and Lumefantrine for Treatment of Uncomplicated Malaria

Sponsor

Victoria Biomedical Research Institute

Enrollment

1,116 participants

Start Date

Jan 20, 2026

Study Type

INTERVENTIONAL

Conditions

Malaria (Plasmodium Falciparum)

Summary

This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa

Eligibility

Min Age: 1 YearMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Artemether/Lumefantrine + Imatinib Mesylate and a drug called Artemether/lumefantrine tablets for people with malaria (plasmodium falciparum). The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGArtemether/lumefantrine tablets

There is no difference

DRUGArtemether/Lumefantrine + Imatinib Mesylate

There is no difference

Locations(1)

Victoria Biomedical Research Institute

Kisumu, Kenya

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07559370

Related Trials

Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults

NCT073852871 location

Dose Finding Trial of R21/Matrix-M in School Children

NCT070746651 location